Newsroom|Lundbeck US

Lundbeck US Charitable Fund Awards More than $4 Million to Organizations Increasing Access to Mental Health Care for US Veterans and the Military Community

Lundbeck US Charitable Fund Awards More than $4 Million to Organizations Increasing Access to Mental Health Care for US Veterans and the Military Community

0

ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company
solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.

Connecting with the Unsung Heroes of Alzheimer’s Disease

Connecting with the Unsung Heroes of Alzheimer’s Disease

Alzheimer's Disease

0

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

0

Lundbeck US Charitable Fund Donates $1 Million to Two Chicagoland Organizations Improving Community Access to Health Care

Lundbeck US Charitable Fund Donates $1 Million to Two Chicagoland Organizations Improving Community Access to Health Care

0

Lundbeck US Charitable Fund: Restoring Brain Health in our Communities

Lundbeck US Charitable Fund: Restoring Brain Health in our Communities

0

The Board of Directors initiates CEO succession

The Board of Directors initiates CEO succession

0

Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

0